Mankind Pharma reported a significant block trade of around 128,000 shares today, indicating substantial investor interest.

Bernstein has recommended investing in Zydus, Lupin, and Sun Pharma, predicting a potential $75 billion growth in India's biopharmaceutical sector over the next decade. The firm believes that innovation, AI integration, and focus on niche therapies could propel this growth, with Zydus being their top choice. Biocon and Mankind Pharma were rated as less promising investments.

Mankind Pharma is considering a price increase for their condoms, as ongoing Middle Eastern conflicts drive up oil costs and potentially boost production expenses.

Mankind Pharma experienced a significant block trade on the NSE, with 107,595 shares exchanging hands for approximately INR 26.9 crore at a price of INR 2,502.50 per share.

PI Industries' earnings disappoint, causing a decline in its shares, while Mankind Pharma experiences growth due to strong earnings. Meanwhile, Godawari Power, Karnataka Bank, and Dredging Corp have all seen an increase in their shares, following robust results.

Mankind Pharma reported a significant increase in Q4 net profit by 36%, reaching ₹554.4 crore for FY26, with quarterly and year-on-year growth of 35.6% and 31.8% respectively. As a result, the company's stock price climbed 3.6% to ₹2,583.4 on May 20, 2026, marking a strong 20.5% growth over the past month.

Mankind Pharma aims to achieve significant growth in the range of 10% or more by the fiscal year 2027, with a strategic focus on managing chronic health conditions.

Mankind Pharma's shares soared following Q4 earnings that outperformed projections, with management optimistic about FY27 results outshining FY26.

Mankind Pharma has been upgraded to a 'Buy' rating by MarketsMojo, reflecting its strong fundamental improvements. This positive change is based on the company's impressive growth trajectory.

Grasim surpasses expectations in Q4, driven by impressive VSF performance, signaling continued growth potential. Mankind Pharma exhibits strong domestic expansion, while Jubilant Food faces margin challenges. Apollo Hospitals receives mixed reviews due to valuation concerns, but a positive outlook following AB Capital's equity raise.

Morgan Stanley maintains a positive outlook for Mankind Pharmaceuticals, boosting its target price to ₹2,735 over the previous ₹2,500, suggesting continued investment optimism towards the company.

Mankind Pharma aims for double-digit global revenue growth by the fiscal year 2027, with a focus on expanding their business beyond India. (Source: Livesquawk)

Mankind Pharmaceuticals expands its reach with the acquisition of a business unit from Bharat Serums, aiming to enhance overall operational efficiency.

Anticipation builds for Mankind Pharma's earnings report, as investors eagerly await details about their potential increase in revenue and profits.

Mankind Pharmaceuticals has announced a significant investment of up to INR 5 billion towards expanding its healthcare division, Mankind Medicare. This expansion is set to occur in stages, as approved by the company.

Mankind Pharma has posted a 12% year-on-year revenue increase, boosted by a 27.1% adjusted EBITDA margin. The domestic business and OTC sectors saw growth of 13% and 20% respectively, although export challenges stemming from geopolitical issues were encountered.

Mankind Pharmaceuticals demonstrates robust operational success, maintaining a recommended price range of 2528-2575. On the other hand, PI Industries continues to underperform, prompting a downward revision of the target price to 3010 due to persistent weak results.

Mankind Pharma reports a 12% increase in Q4 revenue to 34.43 billion INR, with EBITDA surging 36%. Domestic sales, particularly chronic therapies, contributed to a healthy 27% EBITDA margin. International growth remains modest.

Mankind Pharma has set its sights on moderate, teen-digit expansion rates, marking a transition to a more stable, maturing phase compared to its previous high growth of 50-60%. This shift reflects normalization within the business.

Mankind Pharma aspires to achieve an EBITDA margin of around 25.5-26.5% by fiscal year 2027, aiming for a significant boost in profitability. They also expect a robust, double-digit increase in revenue from their global operations by the same year, signaling plans for expanded international growth.

BPCL's Q4 profits dipped by nearly 58% due to substantial one-time costs, leaving them with a net income of approximately ₹3,192 crores. Meanwhile, Novelis, a subsidiary of Hindalco, reported an $84M loss in Q4 as a result of fires at its US facilities. Additionally, Mankind Pharma's profits saw a 30.4% decline year-over-year.

Mankind Pharma has approved a five-year term for its Whole-Time Director and authorized a substantial ₹500 crore investment in a new subsidiary. The decision comes after the successful completion of FY26, which also included the redemption of ₹1,250 crore NCDs and realigning security coverage accordingly.

Mankind Pharma has released its Q4 earnings report, providing a breakdown of essential financial data. Investors are encouraged to review the details for insights into the company's recent performance.

Today, Lenskart, Grasim, Apollo Hospitals, Jubilant Foodworks, BEL, BPCL, and Zee Entertainment will reveal their Q4 earnings. Additionally, IRB Infra, Whirlpool India, Hindalco, and Mankind Pharma are also releasing results. Notably, mixed outcomes have been observed in some companies, particularly BPCL.

Mankind Pharma emphasized their strategic focus during the Q4 conference call, shifting attention towards specialized chronic business operations and research & development initiatives.

BPCL experiences a significant 57.7% decrease in Q4 profits, reporting at ₹3,192 crore, with EBITDA declining 13.8% compared to the previous quarter. Meanwhile, Mankind Pharma witnesses a 30.4% year-on-year profit drop, and JSW Energy increases its stake in Toshiba JSW to 20.7%.

Mankind Pharma's EBITDA increased significantly by 36% in the fourth quarter, reaching ₹9.3 billion compared to last year. This growth led to a notable improvement in the company's profit margin, which stood at 27%.

Mankind Pharma aims for a margin of 25-26.5% by the fiscal year 2027, but this projection is broad due to uncertainties related to costs, product mix, and operational execution.

Today, Bharat Electronics, BPCL, Mankind Pharma, Zee, and Zydus will reveal their Q4 earnings, highlighting key figures such as revenue, profit, and EBITDA. Notable projections include a revenue estimate of Rs 9738.85 crore for BEL, a profit target of Rs 6042.7 crore for BPCL, and an EBITDA margin prediction of 24.3% for Mankind Pharma.

Credit rating agency ICRA has reaffirmed Mankind Pharma's strong ratings, maintaining an AA (Stable) status for its NCDs and A1 grade for commercial papers. The ratings cover fund-based limits of ₹1,250 crore, ₹5,000 crore in NCDs, and ₹600 crore in CP, as reported by the BSE.

Mankind Pharma has broken through a resistance level, confirming a positive trend with increasing prices and volumes. This bullish momentum is indicated by successive bullish candles, suggesting a robust uptrend for the company's stocks.

Mankind Pharmaceuticals will convene on May 19, 2026, to discuss and approve the financial results for FY26, as well as realign its NCD security cover. The trading window remains closed until May 21, with updates available on their official website.

Dabur and Bharat Forge stocks received mixed ratings from brokerages due to differing growth and valuation expectations. On the positive side, sectors like paints and banks have been upgraded with Asian Paints, HDFC Bank, ICICI Bank, SBI, and AU Small Finance Bank showing promising trends.

Morgan Stanley has increased its optimism towards Mankind Pharma, setting a target price of ₹2500. This decision is based on improved execution, including debt reduction, enhanced marketing efforts, efficiency improvements, and temporary leadership adjustments. The pharmaceutical company's recovery from BSV-related issues also plays a role in this positive outlook.

ICICI Securities advises investing in Mankind Pharma, CG Power, and ABB for potential quick profits, according to Jay Thakkar. Meanwhile, the Nifty 50 is experiencing support and resistance levels between 23,300 and 24,300, while BankNifty remains within a range of 53,000-56,000 due to ongoing geopolitical tensions.

Mankind Pharma's domestic formulations showed a stronger 11.5% year-on-year growth compared to IPM's 10.6%, primarily due to increased demand for chronic therapies. With a projected EBITDA compound annual growth rate of 16% from FY26 to FY28, the suggested target price remains at ₹2,640, reaffirming a 'Buy' recommendation. [The Hindu Business Line]

Analysts from various brokerages are optimistic about the future of Sun Pharma, Dr Reddy's, Granules India, and Mankind Pharma, anticipating a potential increase of up to 21% in their share prices.

Mankind Pharma has received a strong credit rating of AA (stable) for long-term and A1 for short-term from CARE for its ₹1,000 crore bank facilities, as per SEBI LODR disclosures. This indicates a positive outlook for the company's financial health and borrowing capacity.

Mankind Pharma, following regulatory difficulties, has decided to close its Sri Lankan unit, WOS Mankind Pharma Lanka Pvt Ltd. This inactive subsidiary doesn't significantly impact the company's overall performance.

Mankind Pharma anticipates increases in drug prices due to escalating costs from the Iran oil crisis, potentially leading to inflation in essential supplies such as APIs, petrochemicals, and medical plastics.